The initial public offering (IPO) of Corona Remedies has garnered massive interest from investors, particularly from institutional participants, on its final day of bidding. As a result, the subscription rate has soared to an impressive 144 times.
The IPO, which opened on Monday, December 8, and closed on December 11, received bids for 62.67 crore shares against the 43.36 lakh shares on offer. The qualified institutional buyer (QIB) segment saw a significant spike in demand, with a subscription rate of 293.80 times, while the non-institutional investor (NII) portion was subscribed 220 times, and the retail investor portion was subscribed 30.39 times.
The grey market premium (GMP) is currently at ₹262, indicating a potential listing price of around ₹1,324, which signals a 25% upside over the upper IPO price of ₹1,062.
Corona Remedies, a pharmaceutical manufacturer based in Gujarat, offers products across various therapeutic categories, including women’s health, cardio-diabetes, pain management, and urology. The company operates two manufacturing facilities, one in Gujarat and the other in Himachal Pradesh.
According to the company's reports, the net profit for Q1 FY26 was ₹46.19 crore, following a full-year net profit of ₹149.43 crore in FY25. The revenue from core operations reached ₹346.54 crore in the second quarter of FY26, while the total revenue for FY25 stood at ₹1,196.41 crore.
Disclaimer: Investors are advised to consult certified experts before making any investment decisions.
Download the TradeKaizen app to practice F&O trading with real-time market data anytime, anywhere.
Get it on Google PlayConnect with fellow traders, share strategies, and improve your trading skills in our Telegram group.
Join Telegram